siRNA / miRNA gene silencing Human 501 Mel and SK Mel 28 FANCD2

Get tips on using Pre-designed and validated siRNA against gene IGFBP1 to perform siRNA / miRNA gene silencing Human - Primary Endometrial Stromal Cells IGFBP1 (Insuline-like growth factor binding protein-1)

Get tips on using beta Tubulin Monoclonal Antibody (2 28 33) to perform Western blotting Tubulin beta

Get tips on using SNAI 1 siRNA and shRNA Plasmids (h) to perform siRNA / miRNA gene silencing Human - MDA-MB-468 SNAI 1

Get tips on using SNAI 1 siRNA and shRNA Plasmids (h) to perform siRNA / miRNA gene silencing Human - MDA-MB-231 SNAI 1

Get tips on using SiRNA silencing human Eph receptor B4, Id: s243 to perform siRNA / miRNA gene silencing Human - HNSCC cell line Eph receptor B4 Polymer / Lipid

Get tips on using SiRNA silencing human Eph receptor B4, Id: 533 to perform siRNA / miRNA gene silencing Human - HNSCC cell line Eph receptor B4 Polymer / Lipid

Get tips on using siGENOME Human MINK1 siRNA to perform siRNA / miRNA gene silencing Human - RMS MINK

Get tips on using siGENOME Human MAP4K2 siRNA to perform siRNA / miRNA gene silencing Human - RMS MAP4K2

Get tips on using siGENOME Human PAK1 siRNA to perform siRNA / miRNA gene silencing Human - HeLa PAK1

Short hairpin or small hairpin RNA (shRNA) is artificial RNA, which has a hairpin loop structure, and uses inherent microRNA (miRNA) machinery to silence target gene expression. This is called RNA interference (RNAi). These can be delivered via plasmids or viral/bacterial vectors. Challenges in shRNA-mediated gene silencing include 1. Off-target silencing, 2. Packaging shRNA encoding lentivirus, and 3. Stable transduction in cells. RNAi has been designed to have anywhere from 19-27 bs, but the most effective design has 19 bp. In case commercial shRNAs are not available, potential target sites can be chosen within exon, 5’- or 3’ UTR, depending on which splice variants of the gene are desired. One should use the latest algorithms and choose at least two different sequences, targeting different regions, in order to have confidence in overcoming off-target effects. A BLAST search after selecting potential design will eliminate potential off-target sequences. For the second challenge, sequencing the vector using primers for either strand (50-100 bp upstream) is suggested, along with using enzymatic digestion on agarose gel for the vector. Next, once the shRNA-containing vector is packaged in a virus, it is important to check the viral titer before transduction. Finally, using a marker in the lentiviral vector (fluorescent protein or antibiotic resistance), along with qPCR for target gene expression can help in determining the efficacy of transduction and shRNA on its target site.